Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: A pilot study

Dementia and Geriatric Cognitive Disorders Extra

Volumn 5, Issue 1, 2015, Pages 51-63

  Hildreth, Kerry L ^a   Van Pelt, Rachael E ^a   Moreau, Kerrie L ^a   Grigsby, Jim ^a   Hoth, Karin F ^a   Pelak, Victoria ^a   Anderson, C Alan ^a   Parnes, Bennett ^a   Kittelson, John ^a   Wolfe, Pamela ^a   Nakamura, Tammie ^a   Linnebur, Sunny A ^a   Trujillo, Jennifer M ^a   Aquilante, Christina L ^a   Schwartz, Robert S ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Exercise; Insulin resistance; Mild cognitive impairment; Pioglitazone

Indexed keywords

OXYGEN; PIOGLITAZONE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; ENDURANCE TRAINING; FEMALE; HEART FAILURE; HUMAN; INSULIN RESISTANCE; MALE; MILD COGNITIVE IMPAIRMENT; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

EID: 84931460446     PISSN: None     EISSN: 16645464     Source Type: Journal    
DOI: 10.1159/000371509     Document Type: Article

References (73)

1. Albert MS, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
2. Mitchell AJ, Shiri-Feshki M: Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252-265.
3. Mitchell AJ, Shiri-Feshki M: Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 2008; 79: 1386-1391.
4. Boyle PA, et al: Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67: 441-445.
5. Petersen RC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
6. Larrieu S, et al: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594-1599.
7. Akomolafe A, et al: Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 2006; 63: 1551-1555.
8. Arvanitakis Z, et al: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
9. Leibson CL, et al: The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci 1997; 826: 422-427.
10. Leibson CL, et al: Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301-308.
11. Luchsinger JA, et al: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635-641.
12. MacKnight C, et al: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14: 77-83.
13. Ott A, et al: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
14. Peila R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-1262.
15. Xu WL, et al: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63: 1181-1186.
16. Luchsinger JA, et al: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-1192.
17. Kuusisto J, et al: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997; 315: 1045-1049.
18. Craft S: The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009; 66: 300-305.
19. Steen E, et al: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
20. Ryan AS: Insulin resistance with aging: effects of diet and exercise. Sports Med 2000; 30: 327-346.
21. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
22. Heyn P, Abreu BC, Ottenbacher KJ: The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004; 85: 1694-1704.
23. Watson GS, et al: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958.
24. Risner ME, et al: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006; 6: 246-254.
25. Hanyu H, et al: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009; 57: 177-179.
26. Sato T, et al: Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011: 32: 1626-1633.
27. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
28. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
29. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
30. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
31. Galasko D, et al: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39.
32. Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
33. Wechsler D: WMS-R Wechsler Memory Scale-Revised Manual. New York, Harcourt Brace Jovanovich, 1987.
34. Rey RA: L'examen psychologique dans les cas d'encéphalopathie traumatique. Arch Psychol 1941; 28: 286-340.
35. Kaplan EF: Boston Naming Test. Philadelphia, Lea & Febiger, 1983.
36. Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms and Commentary, ed 3. New York, Oxford University Press, 2006.
37. Wechsler D: Wechsler Adult Intelligence Scale-Revised. San Antonio, The Psychological Corporation, 1981.
38. Reitan RM: Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
39. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurland LT: Mayo's older Americans normative studies: WAIS-R norms for ages 56 to 97. Clin Neuropsychol 1992; 6(suppl):1-30.
40. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurland LT: Mayo's older Americans normative studies: WMS-R norms for ages 56 to 94. Clin Neuropsychol 1992; 6(suppl):49-82.
41. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurland LT: Mayo's older Americans normative studies: updated AVLT norms for ages 56 to 97. Clin Neuropsychol 1992; 6(suppl):83-104.
42. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC: Neuropsychological tests' norms above age 55: COWAT, BNT, MAE Token, WRAT-R Reading, AMNART, STROOP, TMT and JLO. Clin Neuropsychol 1996; 10: 262-278.
43. Malec JF, Ivnik RJ, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurland LT: Mayo's older Americans normative studies: utility of corrections for age and education for the WAIS-R. Clin Neuropsychol 1992; 6(suppl):31-47.
44. Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Graff-Radford NR, Petersen RC: Mayo's older Americans normative studies: category fluency norms. J Clin Exp Neuropsychol 1998; 20: 194-200.
45. Petersen RC, et al: Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010; 75: 889-897.
46. Petersen RC, et al: Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74: 199-208.
47. Mohs RC, et al: Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S13-S21.
48. Van der Elst W, et al: The Stroop color-word test: influence of age, sex, and education; and normative data for a large sample across the adult age range. Assessment 2006; 13: 62-79.
49. Wechsler D: Wechsler Adult Intelligence Scale, ed 3. San Antonio, The Psychological Corporation, 1997.
50. Esteban-Santillan C, et al: Clock drawing test in very mild Alzheimer's disease. J Am Geriatr Soc 1998; 46: 1266-1269.
51. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223.
52. Van Pelt RE, et al: Acute modulation of adipose tissue lipolysis by intravenous estrogens. Obesity (Silver Spring) 2006; 14: 2163-2172.
53. Liu D, et al: Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia. Diabetologia 1992; 35: 287-290.
54. Jiang Q, Heneka M, Landreth GE: The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008; 22: 1-14.
55. Gold M, et al: Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30: 131-146.
56. Harrington C, et al: Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011; 8: 592-606.
57. Geldmacher DS, et al: A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011; 68: 45-50.
58. Bergman RN, Finegood DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6: 45-86.
59. de la Monte SM, Wands JR: Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-1113.
60. Shemesh E, et al: Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97: 366-376.
61. Rolland Y, Abellan van Kan G, Vellas B: Healthy brain aging: role of exercise and physical activity. Clin Geriatr Med 2010; 26: 75-87.
62. Angevaren M, et al: Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev 200;CD005381.
63. Lautenschlager NT, et al: Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008; 300: 1027-1037.
64. Baker LD, et al: Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 2010; 22: 569-579.
65. Cress ME, et al: Exercise: effects on physical functional performance in independent older adults. J Gerontol A Biol Sci Med Sci 1999; 54:M242-M248.
66. Gozansky WS, et al: Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss. J Clin Endocrinol Metab 2005; 90: 52-59.
67. Kohrt WM, et al: Timing of ibuprofen use and bone mineral density adaptations to exercise training. J Bone Miner Res 2010; 25: 1415-1422.
68. Schenkman M, et al: Exercise for people in early-or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012; 92: 1395-1410.
69. Hildreth KL, et al: Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98: 1891-1900.
70. Uemura K, et al: Cognitive function affects trainability for physical performance in exercise intervention among older adults with mild cognitive impairment. Clin Interv Aging 2013; 8: 97-102.
71. Bonneau GA, Pedrozo WR, Berg G: Adiponectin and waist circumference as predictors of insulin-resistance in women. Diabetes Metab Syndr 2014; 8: 3-7.
72. Zoico E, et al: Adipocytokines, fat distribution, and insulin resistance in elderly men and women. J Gerontol A Biol Sci Med Sci 2004; 59:M935-M939.
73. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(suppl 1):S11-S63.